A Phase 2 interventional study of GW869682 in Obesity, sponsored by GlaxoSmithKline. Completed at 3 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-04-15.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
1,766 studies on the registry are indexed under Weight Loss; 277 are open to participants now.
This study's enrollment of 136 is above the median of 73 across 1,496 interventional studies indexed under Weight Loss.
Browse Weight Loss studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Percentage change in body weight from baseline to Week 12.
Time frame: from baseline to Week 12.
Blood levels of GW869682 at the Week 2 and Week 11.
Time frame: at the Week 2 and Week 11
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline